MAPT and breast carcinoma: Nevertheless, it was of interest to note that tau expression was proposed as an effective predictor for breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy, especially in the ER+ subgroups55, 56, 57, 58, our study could shed new light on the molecular mechanism underlying the utility of tau for individualizing adjuvant chemotherapy in breast cancer patients.